Huawei is testing diabetes risk detection on smartwatches

Huawei's Diabetes Risk Study uses photoplethysmography (PPG), a non-invasive optical technique that measures blood flow changes through the skin by analyzing light reflected from vascular tissue at the wrist. Rather than directly measuring blood glucose like a continuous glucose monitor, the feature analyzes cardiovascular signals captured by PPG sensors because diabetes affects vascular endothelial function, autonomic regulation, and microcirculation—all of which influence PPG waveforms. Research has also identified shared genetic pathways between resting heart rate and diabetes, establishing a physiological link between these cardiovascular signals and metabolic health. Users must wear their smartwatch consistently for three to fourteen days to gather sufficient data before receiving a risk assessment.

No. Huawei explicitly emphasizes that the diabetes risk function is not a medical device and is not intended to diagnose diabetes or replace clinical testing. Instead, it is positioned as a preclinical risk awareness tool designed to increase awareness and prevention, encouraging early engagement with healthcare professionals. Users who receive medium or high risk ratings are advised to seek professional medical consultation for further evaluation and confirmatory diagnostic testing. The feature is only for civilian use and not intended for clinical or hospital deployment, and Huawei offers it free of charge to users.